A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
249actual
Sites
27
Countries
Belgium, Bulgaria, France +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-17 | actual | When the study began enrolling |
| Primary completion | 2025-11-20 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-20 | actual | The whole study's end, after follow-up |
| First posted | 2023-10-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Masseter Muscle Prominence
Interventions
- Drug: BOTOX — also filed as Botulinum Toxin Type A
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFAchievement of 2-grade or more improvement from baseline on the Masseter Muscle Prominence Scale (MMPS) as assessed by the Investigator
measured Day 90
Achievement of 2-grade or more improvement from baseline on the Masseter Muscle Prominence Scale - Participant (MMPS-P) as assessed by the Participant
measured Day 90
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed